Lupin launches generic HIV drug in US market
- Wockhardt under lens for tweaking dosage of essential medicine
- Rampant evergreening in Indian pharma industry
- What does it take to save a newborn’s life?
- 2018 FIFA World Cup: Spain the team to beat in exciting Group B
- Mobile learning start-up EdMobile Labs raises Rs5.5 crore from Unitus Seed Fund, others
New Delhi: Drug firm Lupin has launched generic Abacavir and Lamivudine tablets used for treatment of human immunodeficiency infection in the American market.
The company had earlier received approval from the United States Food and Drug Administration (USFDA) for Abacavir and Lamivudine tablets 600 mg/300 mg, Lupin said in a statement.
Lupin’s tablets are generic versions of ViiV Healthcare Company’s Epzicom tablets, in the same strength, it added.
The product is “indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection,” Lupin said.
Epzicom tablets had US sales of $388.1 million as per IMS MAT December 2016 data, it added.
The company’s cumulative filings with the USFDA now stand at 349, with 213 products already approved, Lupin said.
Shares of Lupin Ltd were trading at Rs1,455 per scrip in the afternoon trade on BSE, down 0.10% from it’s previous close.